Upload

Loading icon Loading...

This video is unavailable.

Study Urges Caution With Lenalidomide Dosage

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to like osumedicalcenter's video.

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to dislike osumedicalcenter's video.

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to add osumedicalcenter's video to your playlist.

Uploaded on Aug 8, 2011

An early phase myeloma trial has unexpectedly revealed that the drug lenalidomide interacts with a protein, called P-glycoprotein, in cells, and that this affects its dose level in the body, say researchers at the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute who conducted the study. The drug is under study in more than 390 clinical trials for cancer and other diseases, and sometimes causes severe and life-threatening side effects. The findings could lead to safer dosing of lenalidomide in a variety of diseases.

Loading icon Loading...

Loading icon Loading...

Loading icon Loading...

Loading icon Loading...

Ratings have been disabled for this video.
Rating is available when the video has been rented.
This feature is not available right now. Please try again later.

Loading icon Loading...

Loading...
Working...
Sign in to add this to Watch Later

Add to